Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pardubice
Clinical trial register · Czechia

Clinical Trials in Pardubice, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Czechia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1513 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:18 UTC
1513
Studies in scope
all four open statuses
780
Recruiting now
open to new participants
300
Lead sponsors
across recruiting studies
Top sites
Prague 1080 Brno 610 Hradec Králové 323 Olomouc 313 Ostrava 282
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Pfizer8 Janssen Research & Development, LLC7 Sanofi6 Takeda5 Eli Lilly and Company5 AbbVie4 AstraZeneca4 Hoffmann-La Roche3 Novartis Pharmaceuticals2 Ipsen2 Bluefin Biomedicine, Inc.2 Charles University, Czech Republic2 argenx2 Masaryk University2 Ascletis Pharma (China) Co., Limited2 Merck Sharp & Dohme LLC2 Spyre Therapeutics, Inc.2 Novo Nordisk A/S2 Aragon Pharmaceuticals, Inc.2 Kymera Therapeutics, Inc.1 Gilead Sciences1 Alumis Inc1 Octapharma1 Viatris Innovation GmbH1 Nektar Therapeutics1 Show all 47
Site location
Prague1080 Brno610 Hradec Králové323 Olomouc313 Ostrava282 Pilsen117 Pardubice92 České Budějovice61 Zlín47 Nový Jičín45 Uherské Hradiště38 Liberec36 Náchod33 Ústí nad Labem33 Ostrava - Poruba32 Ostrava-Poruba32 Brandýs nad Labem30 Jihlava29 Teplice26 Hořovice24 Slaný17 Hodonín16 Kladno15 Hlučín14 Choceň14 Show all 215
All 215 locations
Target enrolment
to

Trials with a site in Pardubice

92 of 1513 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Czechia
Start
Recruiting
Hoffmann-La Roche
Observational
1,800
Pardubice
2026-09-23
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
Pardubice, Prague
2026-09-11
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Pardubice, Prague, Uherské Hradiště
2026-08-31
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Pardubice, Prague, Uherské Hradiště
2026-08-28
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Brno, Broumov, Český Krumlov, Dolní Břežany, Hradec Králové, Náchod, Ostrava, Pardubice
2026-08-24
Recruiting
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
NCT07220915Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
DrugPanzyga
Octapharma
Phase 3
360
Prague, Hradec Králové, Pardubice
2026-06-10
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Ostrava, Pardubice, Prague
2026-05-28
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Hradec Králové, Pardubice, Prague, Slaný, Sternberk, Uherské Hradiště, Vsetín
2026-03-26
Active, closed
Sanofi
Phase 3
59
Hradec Králové, Pardubice, Prague
2026-03-12
Recruiting
Takeda
Phase 3
1,182
Ostrava, Pardubice, Prague, Uherské Hradiště, Zlín
2026-03-11
Active, closed
Pfizer
Phase 3
1,078
Brandys Nad Lebem, Náchod, Ostrava, Pardubice, Prague
2026-02-24
Recruiting
Eli Lilly and Company
Phase 3
900
Brno, Ostrava, Pardubice, Uherské Hradiště
2026-02-09
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Břeclav, Hlučín, Karvina Frystat, Pardubice, Prague, Uherské Hradiště
2026-01-15
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Brno, Olomouc, Ostrava, Pardubice, Prague
2026-01-06
Active, closed
Pfizer
Phase 3
3,578
Brno, Náchod, Ostrava, Pardubice, Prague
2025-12-19
Active, closed
NewAmsterdam Pharma
Phase 3
300
Humpolec, Čáslav, České Budějovice, Hradec Králové, Jílové u Prahy, Krnov, Pardubice, Pilsen
2025-12-11
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Pardubice, Prague
2025-11-24
Recruiting
Pfizer
Phase 2
165
Náchod, Ostrava, Pardubice, Prague
2025-11-20
Active, closed
Bluefin Biomedicine, Inc.
Phase 2/3
210
Ostrava, Pardubice, Prague
2025-11-03
Recruiting
BioNTech SE
Phase 3
558
Nový Jičín, Pardubice, Prague
2025-10-30
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Brno, Kladno, Olomouc, Pardubice, Prague, Praha 1- Mala Strana, Přerov
2025-10-03
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Brno, České Budějovice, Kladno, Olomouc, Pardubice, Prague, Praha 1- Mala Strana, Přerov
2025-10-01
Active, closed
Triveni Bio
Phase 2
95
Ostrava, Pardubice, Prague
2025-08-26
Active, closed
A Study of SPY072 in Rheumatic Disease
NCT07148414Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
DrugSPY072
Spyre Therapeutics, Inc.
Phase 2
285
Hlučín, Moravská Ostrava, Pardubice, Prague, Uherské Hradiště
2025-08-21
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Ostrava, Pardubice, Prague
2025-07-15
Active, closed
TG Therapeutics, Inc.
Phase 3
360
Brno, Hradec Králové, Jihlava, Ostrava, Pardubice, Zlín
2025-07-09
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Brno, Hradec Králové, Jihlava, Pardubice, Prague
2025-06-23
Recruiting
Celgene
Phase 2
200
Brno, Hradec Králové, Prague, Pardubice, Zlín, Teplice
2025-06-05
Recruiting
Boehringer Ingelheim
Phase 2
300
Hradec Králové, Ostrava-Poruba, Pardubice, Prague
2025-06-05
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Brno, Klatovy, Ostrava, Pardubice, Prague
2025-05-27
Recruiting
Pfizer
Phase 3
674
Pilsen, Prague, Pardubice
2025-04-01
Recruiting
Evaluation of Catching Skills in Preschoolers With Motor Difficulties
NCT07028762Development Coordination Disorder, Motor Disabilities
Masaryk University
Observational
40
Pardubice
2025-03-31
Active, closed
Amgen
Phase 3
1,105
Brno, Ostrava, Pardubice, Prague, Pribram VIII
2025-03-17
Recruiting
Early Detection of CTEPH in Patients After APE
NCT06865326Chronic Pulmonary Thromboembolism
Institute of Health Information and Statistics of the Czech Republic
Observational
500
Brno, Havlíčkův Brod, Hradec Králové, Jihlava, Náchod, Olomouc, Ostrava, Pardubice
2025-03-07
Recruiting
Takeda
Phase 3
1,088
Brno, Hlučín, Prague, Uherské Hradiště, Ostrava, Zlín, Pardubice
2025-03-03
Active, closed
Sanofi
Phase 3
216
Hradec Králové, Pardubice, Pilsen, Prague
2025-02-06
Recruiting
Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
NCT06833749Osteoarthritis in the Knee, Obesity
KeyBioscience AG
Phase 2
600
Brno, Hlučín, Hradiště, Pardubice, Prague
2025-01-28
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Náchod, Ostrava, Prague, Brno, Kutná Hora, Nový Jičín, Olomouc, Pardubice
2025-01-08
By invitation
Hearing Screening in Adults Over 50 Years Old
NCT06894927Hearing Loss, Bilateral Sensorineural, Progressive, Hearing Loss, Bilateral (Causes Other Than Tumors), Hearing Loss, Bilateral or Unilateral, Presbyacusis
University Hospital Hradec Kralove
Not applicable
330
Hradec Králové, Pardubice
2025-01-01
Recruiting
Santen SAS
Phase 3
234
Pardubice, Pilsen, Prague
2024-12-30
Recruiting
Pfizer
Phase 3
900
Ostrava - Poruba, Olomouc, Pardubice, Prague, Liberec
2024-10-22
Active, closed
Pfizer
Phase 3
609
Olomouc, Pardubice, Prague
2024-10-21
Active, closed
Ipsen
Phase 2
670
Brno, Choceň, Hradec Králové, Ostrava, Pardubice, Prague
2024-10-10
Active, closed
argenx
Phase 3
141
Brno, Pardubice
2024-09-18
Recruiting
Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening
NCT06549725Pancreas Cancer, Pancreatic Ductal Adenocarcinoma, Hereditary Diseases, Pancreatitis, Chronic
Lipidica, a.s.
Not applicable
419
Prague, Brno, České Budějovice, Hradec Králové, Jablonec nad Nisou, Olomouc, Pardubice, Pilsen
2024-09-10
Active, closed
Takeda
Phase 3
2,099
Náchod, Nový Jičín, Ostrava, Olomouc, Pardubice, Brno, Prague
2024-09-04
Recruiting
Sanofi
Phase 3
160
Brno, Hradec Králové, Ostrava, Pardubice, Prague
2024-08-21
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Brno, Hradec Králové, Pardubice
2024-07-12
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Liberec, Ústní Nad Labem, Brno, České Budějovice, Olomouc, Pardubice, Plzen - Lochotín, Prague
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Brno, Ostrava-Vitkovice, Pardubice, Olomouc
2024-06-10
Recruiting
Motor Development and Early Predictors of Psychomotor Outcomes in Preterm and Term Infants Assessed by MOS-R and Caregiver Questionnaire at 18 and 36 Months
NCT07296003Neurodevelopmental Disorders, Motor Skills Disorders, Infant, Premature Development, Infant, Term Development
Masaryk University
Observational
60
Pardubice
2024-04-19
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Brno, Hradec Králové, Jihlava, Ostrava - Poruba, Pardubice, Prague, Praha 5 - Motol, Teplice
2024-04-16
Active, closed
argenx
Phase 3
119
Brno, Pardubice
2024-04-16
Active, closed
Takeda
Phase 2
213
Hořovice, Brno, Hradec Králové, Ostrava, Ostrava-Poruba, Pardubice, Prague, Ústí nad Labem
2024-03-29
Recruiting
Takeda
Phase 2
268
Hořovice, Brno, České Budějovice, Hradec Králové, Ostrava, Ostrava-Poruba, Pardubice, Prague
2024-03-05
Recruiting
medac GmbH
Phase 3
277
Prague, Olomouc, Ostrava, Pardubice
2024-02-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Ostrava, Pardubice, Prague, Olomouc
2023-12-15
Active, closed
Sanofi
Phase 3
1,655
Brno, Hradec Králové, Jihlava, Ostrava, Pardubice, Prague, Teplice, Zlín
2023-12-13
Active, closed
Nektar Therapeutics
Phase 2
396
Brno, Pardubice, Prague
2023-11-15
Active, closed
AstraZeneca
Phase 3
5,511
Brno, Liberec, Pardubice, Prague
2023-10-05
Active, closed
Gilead Sciences
Phase 3
654
Brno, Olomouc, Pardubice, Prague, Zlín
2023-05-08
Active, closed
Alfasigma S.p.A.
Phase 3
495
Prague, Brno, Ostrava, Pardubice, Uherské Hradiště, Zlín
2023-04-05
Recruiting
Charles University, Czech Republic
Observational
209
Ostrava, Pardubice, Prague, České Budějovice
2023-04-01
Recruiting
AstraZeneca
Phase 3
4,300
Hořovice, Pardubice, Prague, Pragues, Příbram
2023-03-31
Recruiting
Study Comparing Transobturator Cystocele vs. Anterior Vaginal RepairS
NCT05602246Pelvic Organ Prolapse, Cystocele, Cystocele and Incomplete Uterovaginal Prolapse
Charles University, Czech Republic
Not applicable
592
Hradec Králové, Ostrava-Poruba, Pardubice, Pilsen, Prague, Zlín
2022-12-01
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
6,000
Pardubice, Prague, Zlín
2022-11-21
Active, closed
Eli Lilly and Company
Phase 3
8,000
Brno, Hořovice, Hradec Králové, Ostrava, Pardubice, Prague
2022-10-04
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Hradec Králové, Ostrava, Pardubice
2022-09-23
Active, closed
Hoffmann-La Roche
Phase 3
1,300
Brno, Havirov-Podlesi, Hradec Králové, Jihlava, Pardubice, Prague, Teplice
2022-05-03
Active, closed
AstraZeneca
Phase 3
1,035
Hořovice, Hradec Králové, Pardubice, Prague
2022-03-25
Active, closed
Eli Lilly and Company
Phase 3
368
Pardubice, Hradec Králové
2022-03-11
Active, closed
Janssen Research & Development, LLC
Phase 4
411
Brno, Brno-Židenice, Hlučín, Karvina Frystat, Ostrava, Pardubice, Prague, Uherské Hradiště
2021-08-30
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Brno, Bruntál, České Budějovice, Hradec Králové, Jihlava, Liberec, Ostrava - Poruba, Pardubice
2021-08-14
Active, closed
Bristol-Myers Squibb
Phase 3
670
Prague, Uherské Hradiště, Zlín, Ostrava, Pardubice
2021-07-13
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Brno, Brno-Židenice, Hlučín, Ostrava, Pardubice, Prague, Uherské Hradiště, Zlín
2021-06-17
Recruiting
Ipsen
Phase 1/2
240
Hradec Králové, Jihlava, Ostrava, Pardubice, Prague
2021-04-29
Recruiting
SCAD : a Registry of Spontaneous Coronary Artery Dissection
NCT06601270Spontaneous Coronary Artery Dissection
European Society of Cardiology
Observational
1,500
Pardubice, Prague
2021-01-30
Active, closed
AbbVie
Phase 3
527
Prague, České Budějovice, Hradec Králové, Pardubice
2020-09-30
Active, closed
Applied Therapeutics, Inc.
Phase 3
675
Jaroměř, Pardubice, Prague
2019-09-20
Active, closed
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
DrugXeomin
Merz Pharmaceuticals GmbH
Phase 3
603
Brno, Ostrava, Pardubice
2019-09-16
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Hradec Králove, Liberec, Olomouc, Pardubice, Pilsen, Prague, Uherské Hradiště
2019-01-25
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Brno, Havířov, Hradec Králové, Jihlava, Olomouc, Pardubice, Prague, Teplice
2018-12-28
Active, closed
AbbVie
Phase 3
1,336
Prague, Hradec Králové, Pardubice
2018-04-09
Active, closed
Pfizer
Phase 3
1,054
Hradec Králové, Ostrava-Poruba, Pardubice, Prague
2017-12-18
Active, closed
Eli Lilly and Company
Phase 3
5,637
Hořovice, Brno, Ostrava, Pardubice, Prague, Pilsen
2017-07-12
Active, closed
AbbVie
Phase 3
950
Prague, Hradec Králové, Olomouc, Ostrava, Pardubice
2017-01-31
Active, closed
AbbVie
Phase 3
1,629
Hlučín, Olomouc, Prague, Brno, Bruntál, Kladno, Ostrava, Pardubice
2015-12-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Hradec Králove, Liberec, Nový Jicin, Olomouc, Opava, Pardubice, Prague, Zlín
2015-11-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Hradec Králove, Liberec, Nový Jicin, Olomouc, Opava, Pardubice, Prague, Zlín
2015-11-19
Active, closed
Janssen Scientific Affairs, LLC
Observational
21,190
Brno, České Budějovice, Jihlava, Náchod, Nový Jičín, Olomouc, Pardubice, Pilsen
2007-06-21
Active, closed
AstraZeneca
Phase 3
736
Brno, České Budějovice, Pardubice, Prague, Tábor, V Uvalu 84
2005-02-13
Recruiting
Manuel Monreal
Observational
120,000
Hradec Králové, Pardubice, Pilsen
2001-03
Rows per page Showing 1–92 of 92
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Czech investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-czechia/city/pardubice

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Czechia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,513 studies in total at the last sync on 11 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 92 of those studies with a site in Pardubice.

How many clinical trials are recruiting in Pardubice?

39 of the 92 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 51 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pardubice), 92 studies
PhaseStudiesRecruitingShare
Phase 3581863%
Phase 217918.5%
Observational979.8%
Not applicable323.3%
Phase 2/3323.3%
Phase 1/2111.1%
Phase 4101.1%

Most active sponsors

Lead sponsors with the most studies (Pardubice)
Lead sponsorStudiesRecruiting
Pfizer84
Janssen Research & Development, LLC72
Sanofi61
Eli Lilly and Company52
Takeda53
AbbVie40
AstraZeneca41
Hoffmann-La Roche31
Aragon Pharmaceuticals, Inc.20
argenx20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.